Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

A Location-Based Objective Assessment of Physical Activity and Sedentary Behavior in Ambulatory Hemodialysis Patients.

More KM, Blanchard C, Theou O, Cranston A, Vinson AJ, Dipchand C, Kiberd B, Tennankore KK.

Can J Kidney Health Dis. 2019 Aug 28;6:2054358119872967. doi: 10.1177/2054358119872967. eCollection 2019.

2.

A Three-Dimensional In Vitro Coculture Model to Quantify Breast Epithelial Cell Adhesion to Endothelial Cells.

Swaminathan S, Cranston AN, Clyne AM.

Tissue Eng Part C Methods. 2019 Oct;25(10):609-618. doi: 10.1089/ten.TEC.2019.0122. Epub 2019 Sep 26.

PMID:
31441384
3.

Impact of short stature on health-related quality of life in long-term survivors of acute lymphoblastic leukemia in childhood and adolescence.

Collins L, Athale U, Cranston A, Barr R.

J Patient Rep Outcomes. 2018 Dec 7;2(1):59. doi: 10.1186/s41687-018-0084-z.

4.

Targeting Tropomyosin Receptor Kinase in Cutaneous CYLD Defective Tumors With Pegcantratinib: The TRAC Randomized Clinical Trial.

Danilenko M, Stamp E, Stocken DD, Husain A, Zangarini M, Cranston A, Stones R, Sinclair N, Hodgson K, Bowett SA, Roblin D, Traversa S, Plummer R, Veal G, Langtry JAA, Ashworth A, Burn J, Rajan N.

JAMA Dermatol. 2018 Aug 1;154(8):913-921. doi: 10.1001/jamadermatol.2018.1610.

5.

Body composition in long-term survivors of acute lymphoblastic leukemia diagnosed in childhood and adolescence: A focus on sarcopenic obesity.

Marriott CJC, Beaumont LF, Farncombe TH, Cranston AN, Athale UH, Yakemchuk VN, Webber CE, Barr RD.

Cancer. 2018 Mar 15;124(6):1225-1231. doi: 10.1002/cncr.31191. Epub 2017 Dec 12.

6.

Tropomyosin Receptor Antagonism in Cylindromatosis (TRAC), an early phase trial of a topical tropomyosin kinase inhibitor as a treatment for inherited CYLD defective skin tumours: study protocol for a randomised controlled trial.

Cranston A, Stocken DD, Stamp E, Roblin D, Hamlin J, Langtry J, Plummer R, Ashworth A, Burn J, Rajan N.

Trials. 2017 Mar 7;18(1):111. doi: 10.1186/s13063-017-1812-z.

7.

Anthropometry in Long-Term Survivors of Acute Lymphoblastic Leukemia in Childhood and Adolescence.

Collins L, Beaumont L, Cranston A, Savoie S, Nayiager T, Barr R.

J Adolesc Young Adult Oncol. 2017 Jun;6(2):294-298. doi: 10.1089/jayao.2016.0091. Epub 2017 Jan 24.

PMID:
28118063
8.

Health-related quality of life in long-term survivors of acute lymphoblastic leukemia in childhood and adolescence.

Nayiager T, Anderson L, Cranston A, Athale U, Barr RD.

Qual Life Res. 2017 May;26(5):1371-1377. doi: 10.1007/s11136-016-1462-8. Epub 2016 Nov 24.

PMID:
27885548
9.

Soluble pre-fibrillar tau and β-amyloid species emerge in early human Alzheimer's disease and track disease progression and cognitive decline.

Koss DJ, Jones G, Cranston A, Gardner H, Kanaan NM, Platt B.

Acta Neuropathol. 2016 Dec;132(6):875-895. Epub 2016 Oct 21.

10.

Activity Based Profiling of Deubiquitylating Enzymes and Inhibitors in Animal Tissues.

McLellan L, Forder C, Cranston A, Harrigan J, Jacq X.

Methods Mol Biol. 2016;1449:411-9. doi: 10.1007/978-1-4939-3756-1_27.

PMID:
27613053
11.

Physical Activity in Long-term Survivors of Acute Lymphoblastic Leukemia in Childhood and Adolescence: A Cross-sectional Cohort Study.

Nayiager T, Barr RD, Anderson L, Cranston A, Hay J.

J Pediatr Hematol Oncol. 2017 Jan;39(1):15-19.

PMID:
27571119
12.

The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models.

Oplustil O'Connor L, Rulten SL, Cranston AN, Odedra R, Brown H, Jaspers JE, Jones L, Knights C, Evers B, Ting A, Bradbury RH, Pajic M, Rottenberg S, Jonkers J, Rudge D, Martin NM, Caldecott KW, Lau A, O'Connor MJ.

Cancer Res. 2016 Oct 15;76(20):6084-6094. Epub 2016 Aug 22.

13.

Clinical development of new drug-radiotherapy combinations.

Sharma RA, Plummer R, Stock JK, Greenhalgh TA, Ataman O, Kelly S, Clay R, Adams RA, Baird RD, Billingham L, Brown SR, Buckland S, Bulbeck H, Chalmers AJ, Clack G, Cranston AN, Damstrup L, Ferraldeschi R, Forster MD, Golec J, Hagan RM, Hall E, Hanauske AR, Harrington KJ, Haswell T, Hawkins MA, Illidge T, Jones H, Kennedy AS, McDonald F, Melcher T, O'Connor JP, Pollard JR, Saunders MP, Sebag-Montefiore D, Smitt M, Staffurth J, Stratford IJ, Wedge SR; NCRI CTRad Academia-Pharma Joint Working Group.

Nat Rev Clin Oncol. 2016 Oct;13(10):627-42. doi: 10.1038/nrclinonc.2016.79. Epub 2016 Jun 1.

14.

Increased severity of respiratory infections associated with elevated anti-LPS IgG2 which inhibits serum bactericidal killing.

Wells TJ, Whitters D, Sevastsyanovich YR, Heath JN, Pravin J, Goodall M, Browning DF, O'Shea MK, Cranston A, De Soyza A, Cunningham AF, MacLennan CA, Henderson IR, Stockley RA.

J Exp Med. 2014 Aug 25;211(9):1893-904. doi: 10.1084/jem.20132444. Epub 2014 Aug 11.

15.

The immediate effect of triceps surae myofascial trigger point therapy on restricted active ankle joint dorsiflexion in recreational runners: a crossover randomised controlled trial.

Grieve R, Cranston A, Henderson A, John R, Malone G, Mayall C.

J Bodyw Mov Ther. 2013 Oct;17(4):453-61. doi: 10.1016/j.jbmt.2013.02.001. Epub 2013 Apr 21.

PMID:
24139003
16.

Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.

Jaspers JE, Kersbergen A, Boon U, Sol W, van Deemter L, Zander SA, Drost R, Wientjens E, Ji J, Aly A, Doroshow JH, Cranston A, Martin NM, Lau A, O'Connor MJ, Ganesan S, Borst P, Jonkers J, Rottenberg S.

Cancer Discov. 2013 Jan;3(1):68-81. doi: 10.1158/2159-8290.CD-12-0049. Epub 2012 Oct 25.

17.

Neurobehavioral side effects of corticosteroids during active treatment for acute lymphoblastic leukemia in children are age-dependent: report from Dana-Farber Cancer Institute ALL Consortium Protocol 00-01.

Mrakotsky CM, Silverman LB, Dahlberg SE, Alyman MC, Sands SA, Queally JT, Miller TP, Cranston A, Neuberg DS, Sallan SE, Waber DP.

Pediatr Blood Cancer. 2011 Sep;57(3):492-8. doi: 10.1002/pbc.23060. Epub 2011 May 10.

18.

Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts.

Kortmann U, McAlpine JN, Xue H, Guan J, Ha G, Tully S, Shafait S, Lau A, Cranston AN, O'Connor MJ, Huntsman DG, Wang Y, Gilks CB.

Clin Cancer Res. 2011 Feb 15;17(4):783-91. doi: 10.1158/1078-0432.CCR-10-1382. Epub 2010 Nov 19.

19.

The L-Tap - a new two-way tap to prevent inadvertent over transfusion and fluid overload in neonates and infants.

Bergmans E, Cranston A, Thies KC.

Paediatr Anaesth. 2010 Nov;20(11):1055-6. doi: 10.1111/j.1460-9592.2010.03433.x. No abstract available.

PMID:
20964774
20.

Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin.

Hay T, Matthews JR, Pietzka L, Lau A, Cranston A, Nygren AO, Douglas-Jones A, Smith GC, Martin NM, O'Connor M, Clarke AR.

Cancer Res. 2009 May 1;69(9):3850-5. doi: 10.1158/0008-5472.CAN-08-2388. Epub 2009 Apr 21.

21.

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.

Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO, Zander SA, Derksen PW, de Bruin M, Zevenhoven J, Lau A, Boulter R, Cranston A, O'Connor MJ, Martin NM, Borst P, Jonkers J.

Proc Natl Acad Sci U S A. 2008 Nov 4;105(44):17079-84. doi: 10.1073/pnas.0806092105. Epub 2008 Oct 29.

22.

4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1.

Menear KA, Adcock C, Boulter R, Cockcroft XL, Copsey L, Cranston A, Dillon KJ, Drzewiecki J, Garman S, Gomez S, Javaid H, Kerrigan F, Knights C, Lau A, Loh VM Jr, Matthews IT, Moore S, O'Connor MJ, Smith GC, Martin NM.

J Med Chem. 2008 Oct 23;51(20):6581-91. doi: 10.1021/jm8001263. Epub 2008 Sep 19.

PMID:
18800822
23.
24.

RET is constitutively activated by novel tandem mutations that alter the active site resulting in multiple endocrine neoplasia type 2B.

Cranston AN, Carniti C, Oakhill K, Radzio-Andzelm E, Stone EA, McCallion AS, Hodgson S, Clarke S, Mondellini P, Leyland J, Pierotti MA, Whittaker J, Taylor SS, Bongarzone I, Ponder BA.

Cancer Res. 2006 Oct 15;66(20):10179-87.

25.

Health status and health-related quality of life in adolescent survivors of cancer in childhood.

Grant J, Cranston A, Horsman J, Furlong W, Barr N, Findlay S, Barr R.

J Adolesc Health. 2006 May;38(5):504-10.

PMID:
16635760
26.

The Ret(C620R) mutation affects renal and enteric development in a mouse model of Hirschsprung's disease.

Carniti C, Belluco S, Riccardi E, Cranston AN, Mondellini P, Ponder BA, Scanziani E, Pierotti MA, Bongarzone I.

Am J Pathol. 2006 Apr;168(4):1262-75.

27.

A novel activating mutation in the RET tyrosine kinase domain mediates neoplastic transformation.

Cranston A, Carniti C, Martin S, Mondellini P, Hooks Y, Leyland J, Hodgson S, Clarke S, Pierotti M, Ponder BA, Bongarzone I.

Mol Endocrinol. 2006 Jul;20(7):1633-43. Epub 2006 Feb 9.

PMID:
16469774
28.

Novel SRESPHP peptide mediates specific binding to primary medullary thyroid carcinoma after systemic injection.

Böckmann M, Hilken G, Schmidt A, Cranston AN, Tannapfel A, Drosten M, Frilling A, Ponder BA, Pützer BM.

Hum Gene Ther. 2005 Nov;16(11):1267-75.

PMID:
16259560
29.

Germline homozygous mutations at codon 804 in the RET protooncogene in medullary thyroid carcinoma/multiple endocrine neoplasia type 2A patients.

Lesueur F, Cebrian A, Cranston A, Leyland J, Faid TM, Clements MR, Robledo M, Whittaker J, Ponder BA.

J Clin Endocrinol Metab. 2005 Jun;90(6):3454-7. Epub 2005 Mar 1.

PMID:
15741265
30.

Quantitative phenotyping as an efficient means to estimate C-cell number in a knock-in mouse model of MEN2B.

Cranston A, Howard L, Howard CV.

Transgenic Res. 2004 Aug;13(4):339-48.

PMID:
15517993
31.

Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma.

Drosten M, Hilken G, Böckmann M, Rödicker F, Mise N, Cranston AN, Dahmen U, Ponder BA, Pützer BM.

J Natl Cancer Inst. 2004 Aug 18;96(16):1231-9.

PMID:
15316058
33.

Signaling mismatch repair: the mechanics of an adenosine-nucleotide molecular switch.

Fishel R, Acharya S, Berardini M, Bocker T, Charbonneau N, Cranston A, Gradia S, Guerrette S, Heinen CD, Mazurek A, Snowden T, Schmutte C, Shim KS, Tombline G, Wilson T.

Cold Spring Harb Symp Quant Biol. 2000;65:217-24. Review. No abstract available.

PMID:
12760035
34.

C-cell and thyroid epithelial tumours and altered follicular development in transgenic mice expressing the long isoform of MEN 2A RET.

Reynolds L, Jones K, Winton DJ, Cranston A, Houghton C, Howard L, Ponder BA, Smith DP.

Oncogene. 2001 Jul 5;20(30):3986-94.

35.

Chromosomal sequences flanking an efficiently expressed transgene dramatically enhance its expression.

Cranston A, Dong C, Howcroft J, Clark AJ.

Gene. 2001 May 16;269(1-2):217-25.

PMID:
11376953
36.

Isolation and mapping of a human septin gene to a region on chromosome 17q, commonly deleted in sporadic epithelial ovarian tumors.

Russell SE, McIlhatton MA, Burrows JF, Donaghy PG, Chanduloy S, Petty EM, Kalikin LM, Church SW, McIlroy S, Harkin DP, Keilty GW, Cranston AN, Weissenbach J, Hickey I, Johnston PG.

Cancer Res. 2000 Sep 1;60(17):4729-34.

37.

Spontaneous and mutagen-induced transformation of primary cultures of Msh2-/- p53-/- colonocytes.

Sevignani C, Cranston A, Iozzo RV, Fishel R, Calabretta B.

Cancer Res. 1999 Dec 1;59(23):5882-6.

38.

Female embryonic lethality in Msh2-Trp53 nullizygous mice is strain dependent.

Cranston A, Fishel R.

Mamm Genome. 1999 Oct;10(10):1020-2. No abstract available.

PMID:
10501974
39.

Remifentanil infusion for major abdominal surgery in small infants.

Wee LH, Moriarty A, Cranston A, Bagshaw O.

Paediatr Anaesth. 1999;9(5):415-8.

PMID:
10447904
40.

Apoptosis induced by overexpression of hMSH2 or hMLH1.

Zhang H, Richards B, Wilson T, Lloyd M, Cranston A, Thorburn A, Fishel R, Meuth M.

Cancer Res. 1999 Jul 1;59(13):3021-7.

41.

Severe attenuation of the B cell immune response in Msh2-deficient mice.

Vora KA, Tumas-Brundage KM, Lentz VM, Cranston A, Fishel R, Manser T.

J Exp Med. 1999 Feb 1;189(3):471-82.

42.
43.

Increased hypermutation at G and C nucleotides in immunoglobulin variable genes from mice deficient in the MSH2 mismatch repair protein.

Phung QH, Winter DB, Cranston A, Tarone RE, Bohr VA, Fishel R, Gearhart PJ.

J Exp Med. 1998 Jun 1;187(11):1745-51.

44.

Female embryonic lethality in mice nullizygous for both Msh2 and p53.

Cranston A, Bocker T, Reitmair A, Palazzo J, Wilson T, Mak T, Fishel R.

Nat Genet. 1997 Sep;17(1):114-8.

PMID:
9288110
45.

The incidence of post dural puncture headache in children.

Wee LH, Lam F, Cranston AJ.

Anaesthesia. 1996 Dec;51(12):1164-6.

46.

Postoperative airway problems in a child with Crouzon's syndrome.

Payne JF, Cranston AJ.

Paediatr Anaesth. 1995;5(5):331-3. No abstract available.

PMID:
7489477
47.

Information exchange.

Duff L, Stokes J, Taylor M, Cranston A, Cook J, Heffer M, George V K.

Nurs Stand. 1991 Jul 24;5(44):42-43.

PMID:
27665656
48.

Assessment of a hygroscopic heat and moisture exchanger for paediatric use.

Wilkinson KA, Cranston A, Hatch DJ, Fletcher ME.

Anaesthesia. 1991 Apr;46(4):296-9.

49.

Improving trauma care.

Cranston A.

Acad Med. 1989 May;64(5):249. No abstract available.

PMID:
2713004
50.

Psychology in the Veterans Administration: a storied history, a vital future.

Cranston A.

Am Psychol. 1986 Sep;41(9):990-5. No abstract available.

PMID:
3532880

Supplemental Content

Loading ...
Support Center